Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5.
Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Blumenkranz MS, et al. Among authors: bressler nm, bressler sb. Arch Ophthalmol. 2002 Oct;120(10):1307-14. doi: 10.1001/archopht.120.10.1307. Arch Ophthalmol. 2002. PMID: 12365909 Clinical Trial.
Improvement after verteporfin therapy.
Anand R, Bressler NM, Bressler SB, Gray TE, Harvey P, Haynes L, Koester JM, Manos KS, Miller JW, Murphy S, Reaves A, Sickenberg M, Singerman LJ, Strong A, Stur M; "Improvement After Verteporfin Therapy" Writting Committee for TAP Study Group. Anand R, et al. Among authors: bressler nm, bressler sb. Arch Ophthalmol. 2003 Mar;121(3):415-6. doi: 10.1001/archopht.121.3.415. Arch Ophthalmol. 2003. PMID: 12617718 No abstract available.
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3.
Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JI, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA. Blinder KJ, et al. Among authors: bressler nm, bressler sb. Ophthalmology. 2003 Apr;110(4):667-73. doi: 10.1016/s0161-6420(02)01998-x. Ophthalmology. 2003. PMID: 12689884 Clinical Trial.
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network; Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. Diabetic Retinopathy Clinical Research Network, et al. Among authors: bressler nm. Ophthalmology. 2007 Oct;114(10):1860-7. doi: 10.1016/j.ophtha.2007.05.062. Epub 2007 Aug 15. Ophthalmology. 2007. PMID: 17698196 Free PMC article. Clinical Trial.
Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration.
Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group; Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids, and Photodynamic Therapy (NAPP) Trial Research Group, et al. Among authors: bressler nm. Ophthalmology. 2007 Sep;114(9):1713-21. doi: 10.1016/j.ophtha.2007.03.071. Ophthalmology. 2007. PMID: 17822977 Clinical Trial.
429 results